News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KemPharm, Inc. Receives Positive Feedback From FDA on KP201 Clinical Plan


11/20/2012 9:12:01 AM

NORTH LIBERTY, Iowa--(BUSINESS WIRE)--KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today a successful Type B meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201. The meeting was held to obtain input from the Agency in regard to the remaining clinical and non-clinical program required for submission of a new drug application (NDA) for KP201.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES